This protocol is judged by an institutional evaluate board, an unbiased group that evaluations any medical trials involving people. If a review involves a Schedule I drug, when the board approves the protocol as ethical, the researchers have to make an application for an investigational new drug (IND) variety in the FDA.Medications can also include